Bio-Rad Laboratories Profit Margin 2010-2022 | BIO.B

Current and historical gross margin, operating margin and net profit margin for Bio-Rad Laboratories (BIO.B) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Bio-Rad Laboratories net profit margin as of September 30, 2022 is -215.16%.
Bio-Rad Laboratories Annual Profit Margins
Bio-Rad Laboratories Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $12.069B $2.923B
BIO-RAD LABORATORIES, INC. manufactures and supplies to life sciences research, healthcare, analytical chemistry, semiconductor and other markets a broad range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $171.581B 10.47
GSK (GSK) United Kingdom $71.504B 8.96
QIAGEN (QGEN) Netherlands $11.167B 19.06
Ginkgo Bioworks Holdings (DNA) United States $3.492B 0.00
Myovant Sciences (MYOV) United Kingdom $2.595B 0.00
Arcus Biosciences (RCUS) United States $2.459B 36.91
Biohaven (BHVN) United States $1.112B 0.00
Emergent Biosolutions (EBS) United States $0.588B 4.62
Zymeworks (ZYME) Canada $0.480B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.270B 0.00
Enzo Biochem (ENZ) United States $0.092B 0.00
SQZ Biotechnologies (SQZ) United States $0.042B 0.00
Gelesis Holdings (GLS) United States $0.032B 0.00
Ambrx Biopharma (AMAM) United States $0.020B 0.00